Inhaled Insulin Delivery Systems for Diabetes Management

Inhaled insulin delivery represents a significant advance in the management of both type 1 and type 2 diabetes by offering a non-invasive alternative to subcutaneous injections. By harnessing the large surface area and rich vascularisation of the pulmonary alveoli, these systems facilitate rapid absorption and allow for more physiologically aligned insulin profiles. Early formulations faced challenges in achieving consistent dosing and maintaining pulmonary safety, but recent innovations in dry-powder technology, device design and particle engineering have markedly improved reproducibility and bioavailability. Modern inhaled insulin is typically formulated as an ultrafine powder that is dispersed into the airways via a handheld inhaler, yielding an onset of action close to that of endogenous prandial insulin. This approach has been shown to enhance post-prandial glucose control, reduce injection burden and potentially improve adherence in individuals who are needle averse. Ongoing efforts are directed towards optimising deposition efficiency, ensuring long-term pulmonary safety and integrating closed-loop control systems for automated dosing. The global significance of inhaled insulin lies in its potential to expand access to insulin therapy, particularly in resource-limited settings where cold chain logistics and injection training present barriers to optimal glycaemic management.

Research from Nature Portfolio

Recent studies have employed advanced computer simulations to disentangle the contributions of inhaled insulin versus endogenous secretion. A dynamic in-silico modelling approach has been developed to quantify exogenous and endogenous plasma insulin appearance during standardised meal tests, revealing that inhaled formulations can deliver approximately 42 % of the administered dose to systemic circulation while attenuating endogenous insulin release in the early post-prandial period. This modelling framework also permits individual estimates of bioavailability and offers a platform for optimising dosing algorithms and inhaler design, thereby informing both clinical practice and device development.

Inhaled Insulin Delivery Systems for Diabetes Management publication trend

The graph below shows the total number of articles in inhaled insulin delivery systems for diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Bioavailability: The proportion of an administered dose that reaches systemic circulation in an active form.

Pharmacokinetics (PK): The study of the absorption, distribution, metabolism and excretion of a drug.

Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs and their mechanisms of action.

In-silico modelling: Computer-based simulation techniques used to predict biological processes and drug behaviour in virtual settings.

Technosphere Insulin: An ultrafine dry-powder insulin formulation designed for pulmonary delivery, characterised by rapid dissolution and absorption.

References

1. An in-silico modeling approach to separate exogenous and endogenous plasma insulin appearance, with application to inhaled insulin. Scientific Reports (2024).
2. Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice. Journal of Diabetes Research (2018).
3. Comparative Analysis of Inhaled Insulin With Other Types in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Cureus (2022).
4. Impacto da Terapia com Insulina Inalada no Controle Glicêmico de Pacientes com Diabetes Tipo 1. Brazilian Journal of Implantology and Health Sciences (2024).